Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q1 FY23 results · Apr–Jun 2022
Neuland Laboratories reported revenue from operations of ₹221.17 crore (up 10.1% from Q1 FY22) and net profit of ₹9.97 crore (up 14.1% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 221.17 | 200.89 | +10.1% | 255.87 | −13.6% |
| Other income | 0.51 | 2.06 | −75.1% | 0.63 | −19.0% |
| Total income | 221.68 | 202.94 | +9.2% | 256.50 | −13.6% |
| Profit before tax | 13.46 | 12.07 | +11.5% | 24.28 | −44.6% |
| Net profit for the period | 9.97 | 8.73 | +14.1% | 21.78 | −54.2% |
| EPS, basic (₹) | 7.77 | 6.81 | +14.1% | 17.01 | −54.3% |
| Net margin (%) | 4.5 | 4.3 | 8.5 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 221.17 | 200.89 | +10.1% | 255.87 | −13.6% |
| Other income | 0.51 | 2.06 | −75.1% | 0.63 | −18.9% |
| Total income | 221.68 | 202.94 | +9.2% | 256.50 | −13.6% |
| Profit before tax | 13.33 | 11.99 | +11.2% | 24.12 | −44.7% |
| Net profit for the period | 9.84 | 8.65 | +13.8% | 21.83 | −54.9% |
| EPS, basic (₹) | 7.67 | 6.74 | +13.8% | 17.01 | −54.9% |
| Net margin (%) | 4.4 | 4.3 | 8.5 |
Consolidated
- Filed with BSE
- 03 Aug 2022, 18:14 IST
- Board meeting
- 03 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Aug 2022, 18:14 IST
- Board meeting
- 03 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE